Predicting respiratory failure in patients infected by SARS-CoV-2 by admission sex-specific biomarkers.
Angiotensin1-7
Biomarkers
COVID-19
Estrogen
Gender
Sex
Testosterone
Journal
Biology of sex differences
ISSN: 2042-6410
Titre abrégé: Biol Sex Differ
Pays: England
ID NLM: 101548963
Informations de publication
Date de publication:
22 11 2021
22 11 2021
Historique:
received:
30
08
2021
accepted:
09
11
2021
entrez:
23
11
2021
pubmed:
24
11
2021
medline:
18
12
2021
Statut:
epublish
Résumé
Several biomarkers have been identified to predict the outcome of COVID-19 severity, but few data are available regarding sex differences in their predictive role. Aim of this study was to identify sex-specific biomarkers of severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19. Plasma levels of sex hormones (testosterone and 17β-estradiol), sex-hormone dependent circulating molecules (ACE2 and Angiotensin1-7) and other known biomarkers for COVID-19 severity were measured in male and female COVID-19 patients at admission to hospital. The association of plasma biomarker levels with ARDS severity at admission and with the occurrence of respiratory deterioration during hospitalization was analysed in aggregated and sex disaggregated form. Our data show that some biomarkers could be predictive both for males and female patients and others only for one sex. Angiotensin1-7 plasma levels and neutrophil count predicted the outcome of ARDS only in females, whereas testosterone plasma levels and lymphocytes counts only in males. Sex is a biological variable affecting the choice of the correct biomarker that might predict worsening of COVID-19 to severe respiratory failure. The definition of sex specific biomarkers can be useful to alert patients to be safely discharged versus those who need respiratory monitoring.
Sections du résumé
BACKGROUND
Several biomarkers have been identified to predict the outcome of COVID-19 severity, but few data are available regarding sex differences in their predictive role. Aim of this study was to identify sex-specific biomarkers of severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19.
METHODS
Plasma levels of sex hormones (testosterone and 17β-estradiol), sex-hormone dependent circulating molecules (ACE2 and Angiotensin1-7) and other known biomarkers for COVID-19 severity were measured in male and female COVID-19 patients at admission to hospital. The association of plasma biomarker levels with ARDS severity at admission and with the occurrence of respiratory deterioration during hospitalization was analysed in aggregated and sex disaggregated form.
RESULTS
Our data show that some biomarkers could be predictive both for males and female patients and others only for one sex. Angiotensin1-7 plasma levels and neutrophil count predicted the outcome of ARDS only in females, whereas testosterone plasma levels and lymphocytes counts only in males.
CONCLUSIONS
Sex is a biological variable affecting the choice of the correct biomarker that might predict worsening of COVID-19 to severe respiratory failure. The definition of sex specific biomarkers can be useful to alert patients to be safely discharged versus those who need respiratory monitoring.
Identifiants
pubmed: 34809704
doi: 10.1186/s13293-021-00407-x
pii: 10.1186/s13293-021-00407-x
pmc: PMC8607227
doi:
Substances chimiques
Angiotensins
0
Biomarkers
0
Testosterone
3XMK78S47O
Estradiol
4TI98Z838E
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Subventions
Organisme : Ministero della Salute
ID : COVID-2020-12371817
Investigateurs
Manuela Macchione
(M)
Rachele Di Lorenzo
(R)
Marta Camici
(M)
Roberta Gagliardini
(R)
Serena Vita
(S)
Gaetano Maffongelli
(G)
Eugenia Milozzi
(E)
Francesca Faraglia
(F)
Carlotta Cerva
(C)
Silvia Mosti
(S)
Davide Roberto Donno
(DR)
Pierangelo Chinello
(P)
Veronica Bordoni
(V)
Alessandra Sacchi
(A)
Eleonora Tartaglia
(E)
Rita Casetti
(R)
Germana Grassi
(G)
Eleonora Cimini
(E)
Maria Luisa Dupuis
(ML)
Simona Anticoli
(S)
Katia Fecchi
(K)
Maria Bellenghi
(M)
Rossella Puglisi
(R)
Gianfranco Mattia
(G)
Giada Pontecorvi
(G)
Informations de copyright
© 2021. The Author(s).
Références
JAMA Netw Open. 2021 Jul 1;4(7):e2116901
pubmed: 34255046
J Am Coll Cardiol. 2009 Sep 1;54(10):919-27
pubmed: 19712802
J Clin Med. 2021 Feb 25;10(5):
pubmed: 33668766
Am Heart J Plus. 2021 Mar;3:100011
pubmed: 34169297
Front Pediatr. 2021 Mar 30;8:607647
pubmed: 33859967
Cancer Discov. 2014 Nov;4(11):1310-25
pubmed: 25122198
N Engl J Med. 2017 Aug 10;377(6):562-572
pubmed: 28792873
J Biomol Struct Dyn. 2021 Jul;39(10):3605-3614
pubmed: 32396773
Lancet Respir Med. 2020 Nov;8(11):1154-1158
pubmed: 33131609
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):637-639
pubmed: 32428864
Mayo Clin Proc. 2020 Oct;95(10):2189-2203
pubmed: 33012349
Biol Sex Differ. 2021 Jan 29;12(1):16
pubmed: 33514386
Cell Death Discov. 2020 May 26;6:37
pubmed: 32499922
Nature. 2017 Oct 11;550(7675):244-248
pubmed: 29022598
J Allergy Infect Dis. 2020;1(2):38-48
pubmed: 33196058
J Endocrinol Invest. 2005;28(11 Suppl Proceedings):116-9
pubmed: 16760639
Exp Biol Med (Maywood). 2017 Aug;242(14):1412-1423
pubmed: 28661206
Acta Pharmacol Sin. 2020 Sep;41(9):1255-1257
pubmed: 32581256
SN Compr Clin Med. 2020;2(10):1761-1766
pubmed: 32864572
Front Endocrinol (Lausanne). 2021 Mar 16;12:607179
pubmed: 33796068
JAMA Netw Open. 2021 May 3;4(5):e2111398
pubmed: 34032853
J Clin Med. 2018 Dec 14;7(12):
pubmed: 30558178
Monaldi Arch Chest Dis. 2020 May 25;90(2):
pubmed: 32449614
Front Immunol. 2018 Oct 04;9:2279
pubmed: 30337927
Int J Infect Dis. 2021 Jul;108:244-251
pubmed: 34023492
J Infect. 2021 Mar;82(3):414-451
pubmed: 33131700
Am J Emerg Med. 2021 Apr;42:60-69
pubmed: 33453617
Scand J Immunol. 2021 Jun;93(6):e13039
pubmed: 33710663
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744
pubmed: 29562364
PLoS One. 2021 Sep 10;16(9):e0257051
pubmed: 34506535
Clin Infect Dis. 2020 Jul 28;71(15):870-874
pubmed: 32215613
Clin Ther. 2021 Mar;43(3):557-571.e1
pubmed: 33583576
Crit Care. 2020 Nov 16;24(1):647
pubmed: 33198786
PLoS One. 2021 Apr 28;16(4):e0250774
pubmed: 33909684
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Clin Infect Dis. 2021 May 4;72(9):e240-e248
pubmed: 32697835
Med Clin (Engl Ed). 2021 Jun 11;156(11):541-546
pubmed: 34109275
Curr Drug Targets. 2017;18(11):1301-1313
pubmed: 27469342
Ann Oncol. 2020 Oct;31(10):1419-1420
pubmed: 32653425
Andrology. 2021 Jan;9(1):88-98
pubmed: 32436355
BMC Med. 2020 Nov 25;18(1):369
pubmed: 33234138
Drug Dev Res. 2020 Aug;81(5):537-540
pubmed: 32129518
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
Med Intensiva (Engl Ed). 2021 Jan-Feb;45(1):42-55
pubmed: 32646669
Front Physiol. 2021 Feb 09;12:627260
pubmed: 33633588